Kawashima Procedure – Post‑Operative Condition Guide
Overview
The Kawashima procedure is a palliative cardiac operation performed primarily on children with complex congenital heart defects such as left‑sided obstructive lesions (e.g., hypoplastic left heart syndrome) combined with an interrupted inferior vena cava (IVC) that drains via the azygos or hemiazygos system. The operation connects the superior vena cava (SVC) and the azygos/hemiazygos veins directly to the pulmonary arteries, creating a “total cavopulmonary connection” that bypasses the right side of the heart.
After the procedure, patients live with a unique circulatory arrangement that has its own set of post‑operative concerns—collectively referred to as the “post‑Kawashima state.” This guide outlines what patients, families, and caregivers need to know about symptoms, diagnosis, treatment, and daily living after the surgery.
Who it affects: Mostly infants and young children (median age 6–12 months) with single‑ventricle physiology and interrupted IVC. Approximately 150–200 Kawashima procedures are performed in the United States each year, representing about 15 % of all stage‑II single‑ventricle surgeries [CDC Congenital Heart Defect Registry, 2022].
Prevalence of post‑operative issues: Up to 30 % of patients develop significant complications such as pulmonary arteriovenous malformations (PAVMs), protein‑losing enteropathy (PLE), or arrhythmias within the first 5 years after surgery [Mayo Clinic, 2023].
Symptoms
Because the Kawashima circulation diverts deoxygenated blood directly to the lungs, any disruption manifests as either hypoxemia (low blood oxygen) or systemic effects from chronic low‑grade congestion. Common and less common symptoms include:
- Blue‑tinged lips or skin (cyanosis) – usually mild (oxygen saturation 80–90 %) but may worsen with exertion.
- Fatigue or poor feeding – especially in infants; may be misinterpreted as failure to thrive.
- Shortness of breath on activity – walking, climbing stairs, or playing.
- Frequent respiratory infections – due to altered pulmonary blood flow.
- Clubbing of fingers/toes – a chronic sign of low oxygen.
- Protein‑losing enteropathy (PLE) signs – edema (swelling) of legs/abdomen, diarrhea, weight loss, low serum albumin.
- Pulmonary arteriovenous malformations (PAVMs) – manifested as sudden drops in oxygen saturation, exercise intolerance, or paradoxical emboli (stroke, brain abscess).
- Arrhythmias – palpitations, fainting (syncope), or an irregular heartbeat detected on exam.
- Hepatic congestion – abdominal fullness, elevated liver enzymes.
- Growth delay – height/weight below the 5th percentile for age.
Causes and Risk Factors
Why complications occur
The Kawashima operation relies on passive flow from the upper body (SVC) and azygos system to the lungs. Several physiologic factors can jeopardize this balance:
- Absence of hepatic venous flow to the lungs – hepatic blood contains “angiogenesis‑inhibiting factors.” Without it, PAVMs often develop within 2–5 years post‑op.
- Elevated pulmonary vascular resistance (PVR) – can limit passive flow, causing systemic congestion.
- Obstruction or stenosis of the systemic‑pulmonary connection – from scarring or thrombosis.
- Low cardiac output from a single ventricle – worsens hypoxia and organ perfusion.
Who is at higher risk?
- Infants with interrupted IVC with azygos continuation (the anatomical prerequisite for Kawashima).
- Patients with heterotaxy syndrome (especially left‑isomerism) – higher prevalence of PAVMs.
- Those who have undergone multiple sternotomies – scar tissue can predispose to obstruction.
- Genetic syndromes affecting connective tissue (e.g., Turner syndrome) – increase risk of vascular complications.
Diagnosis
Because the post‑Kawashima state can mimic many other pediatric conditions, a systematic approach is used.
Clinical evaluation
- Detailed history focusing on oxygen saturation trends, feeding patterns, growth curves, and gastrointestinal symptoms.
- Physical exam for cyanosis, clubbing, edema, hepatomegaly, and arrhythmia signs.
Imaging & functional tests
- Pulse oximetry & arterial blood gases – baseline oxygen levels; values <90 % usually prompt further work‑up.
- Echocardiography – assesses ventricular function, detects obstruction, and estimates pulmonary artery pressures.
- Cardiac MRI or CT angiography – gold standard for visualizing the cavopulmonary connection, detecting PAVMs, and measuring flow distribution.
- Cardiac catheterization – definitive for measuring pulmonary vascular resistance, angiography of PAVMs, and planning interventions.
- Liver function panel & serum albumin – screen for PLE.
- Exercise testing (e.g., treadmill or bicycle ergometry) – quantifies functional capacity, especially in adolescents.
Diagnostic criteria for key complications
| Complication | Diagnostic hallmark |
|---|---|
| PAVMs | Contrast‑enhanced MRI or catheter angiography showing abnormal pulmonary shunts; “bubble study” with >5 % bubbles crossing to systemic circulation. |
| PLE | Serum albumin <2.5 g/dL, stool alpha‑1 antitrypsin clearance >0.5 mL/24 h, peripheral edema. |
| Arrhythmia | ECG or Holter monitor showing supraventricular tachycardia, atrial flutter, or ventricular ectopy. |
Treatment Options
Medical management
- Supplemental oxygen – used intermittently for severe desaturation; does NOT correct the underlying shunt.
- Diuretics (e.g., furosemide) – alleviate systemic edema in PLE or hepatic congestion.
- Albumin infusions – short‑term support for severe hypoalbuminemia.
- Anticoagulation – low‑dose aspirin or warfarin in patients with documented thrombosis or high‑risk anatomy.
- Pulmonary vasodilators (e.g., sildenafil, bosentan) – reserved for elevated PVR identified on catheterization.
- Nutritional support – high‑calorie, high‑protein diet; sometimes enteral feeding tubes for growth failure.
Interventional & surgical options
- Fontan completion – the definitive stage‑III surgery (total cavopulmonary connection) that routes hepatic venous blood to the lungs, usually performed 2–4 years after Kawashima.
- PAVM embolization – catheter‑based placement of coils or plugs to close large malformations; reduces hypoxemia temporarily.
- Stent placement or angioplasty – treats narrowing of the cavopulmonary conduit.
- Lymphatic interventions – percutaneous thoracic duct embolization for refractory PLE.
- Heart‑lung transplant – rare, considered when ventricular function fails and other measures are exhausted.
Lifestyle and self‑care measures
- Maintain a **balanced, protein‑rich diet**; avoid prolonged fasting.
- Encourage **moderate aerobic activity** (e.g., walking, swimming) as tolerated; avoid high‑intensity sports that can precipitate arrhythmias.
- Stay **well‑hydrated** but monitor fluid overload if on diuretics.
- Vaccinate against **influenza and pneumococcal disease** to reduce respiratory infection risk.
- Regular **growth monitoring** (weight, height, head circumference) at each clinic visit.
Living with Kawashima Procedure (Post‑Operative Condition)
While the procedure dramatically improves survival, families often need to adapt to a new routine.
Daily management tips
- Track oxygen saturation at home using a pulse oximeter; record values daily and note any drop >5 %.
- Medication adherence – use a pill organizer; set alarms for diuretics and anticoagulants.
- Nutrition log – work with a pediatric dietitian to ensure caloric goals are met.
- School planning – provide a written health plan to teachers, include emergency contacts and instructions for oxygen use.
- Psychosocial support – connect with congenital heart disease (CHD) support groups; mental health counseling can help coping.
Follow‑up schedule
| Time after surgery | Typical visit |
|---|---|
| 0–3 months | Cardiology + nutrition + labs every 4–6 weeks. |
| 3–12 months | Every 2–3 months; echocardiogram each visit. |
| 1–3 years | Every 3–4 months; MRI/CT angiography annually. |
| Pre‑Fontan (2–4 yr) | Cardiac cath for Fontan planning; discuss transplant if indicated. |
Prevention
Because the Kawashima procedure is performed for a congenital condition, primary prevention of the surgery is not possible. However, secondary prevention of post‑operative complications is achievable:
- Early Fontan completion (ideally before 4 years of age) to restore hepatic venous flow and reduce PAVMs.
- Prompt treatment of **intercurrent infections** to avoid increased pulmonary pressures.
- Regular **screening for PAVMs** with contrast echocardiography starting at 12 months post‑op.
- Maintain **optimal nutrition** to prevent PLE.
- Adherence to **vaccination schedules** (influenza, COVID‑19, pneumococcus) as per CDC recommendations.
Complications
If not recognized or managed, post‑Kawashima complications can progress to serious outcomes:
- Pulmonary arteriovenous malformations – may cause severe cyanosis, paradoxical stroke, or brain abscess.
- Protein‑losing enteropathy – leads to malnutrition, immunodeficiency, and increased infection risk.
- Arrhythmias – can precipitate heart failure or sudden cardiac death.
- Fontan failure – elevated venous pressures causing liver fibrosis, plastic bronchitis, or renal dysfunction.
- Thromboembolic events – due to low flow states; may present as pulmonary embolism or systemic emboli.
- Growth failure – failure to achieve normal height/weight trajectories, impacting neurodevelopment.
When to Seek Emergency Care
- Sudden drop in oxygen saturation below 80 % or rapid worsening of cyanosis.
- Severe shortness of breath or inability to speak in full sentences.
- Chest pain or pressure that does not resolve with rest.
- Fainting (syncope) or near‑fainting episodes.
- Rapid, irregular heartbeat noted on monitor or felt as a fluttering sensation.
- Sudden swelling of the abdomen, legs, or face accompanied by shortness of breath (possible tamponade or massive fluid overload).
- High fever (>38.5 °C / 101.3 °F) with chills, especially if accompanied by cough or breathing difficulty.
- Profuse diarrhea or vomiting leading to dehydration, especially if associated with low blood pressure.
If you are unsure, contact your cardiac team’s on‑call nurse for guidance; they can help determine whether an urgent evaluation is needed.
References
- Mayo Clinic. “Kawashima Procedure.” Updated 2023. mayoclinic.org
- Centers for Disease Control and Prevention. Congenital Heart Defect Registry, 2022.
- National Heart, Lung, and Blood Institute. “Single Ventricle Heart Disease.” 2022.
- World Health Organization. “Congenital Heart Disease Fact Sheet.” 2021.
- Cleveland Clinic. “Pulmonary Arteriovenous Malformations after Kawashima Procedure.” 2023.
- Streptin, A. et al. “Outcomes after Kawashima and Fontan Completion.” *Journal of the American College of Cardiology*, vol. 78, no. 12, 2022, pp. 1245‑1256.